

Anti-EGFR (Cetuximab), Chimeric Antibody
Catalog # ABV11757**Specification**

Anti-EGFR (Cetuximab), Chimeric Antibody - Product Information

Application	E
Primary Accession	AAI18666
Reactivity	Human
Host	Human/Mouse Chimeric
Clonality	Monoclonal
Isotype	Human IgG1

Anti-EGFR (Cetuximab), Chimeric Antibody - Additional Information

Application & Usage	Neutralization : 1-20 µg/ml; ELISA: 2 µg/ml
Alias Symbol	EGFR
Other Names	
Erbix, ErbB1	

Appearance
Colourless liquid**Formulation**
100 ug (2mg/ml) of antibody in Phosphate buffered saline, pH 7.4.**Reconstitution & Storage**
-20 °C**Background Descriptions****Precautions**

Anti-EGFR (Cetuximab), Chimeric Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Anti-EGFR (Cetuximab), Chimeric Antibody - Protein Information**Anti-EGFR (Cetuximab), Chimeric Antibody - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)

- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-EGFR (Cetuximab), Chimeric Antibody - Images

Anti-EGFR (Cetuximab), Chimeric Antibody - Background

Cetuximab is a recombinant human/mouse chimeric epidermal growth factor receptor (EGFR) monoclonal antibody. Epidermal growth factor receptor (EGFR) is a receptor found on both normal and tumor cells that is important for cell growth. Cetuximab is an EGFR inhibitor, used to treat cancer by blocking the activity of EGFR and keep cancer from growing. Cetuximab can form a bridge that trigger an immune response by binding to the EGFR on the tumor cells. It is used for the treatment of EGFR-expressing, metastatic colorectal cancer.